| Name | Title | Contact Details |
|---|---|---|
Chris Knight |
Director of Cyber Security | Profile |
Titanium Healthcare is one of the nation`s leading providers for specialty healthcare needs. Operating since October 2014 throughout 46 states, Titanium leads the way in compounded pharmaceuticals and nutraceuticals, injection kit solutions, pharmacogenetic testing and urine toxicology screening.
MedTrak Pharmacy Svcs is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HelixVM is a cutting-edge digital health start-up revolutionizing the way healthcare is delivered. Our goal is to free both physicians and patients from the repetitive and time-consuming aspects of routine care, while simultaneously increasing patient access to care and physician income. We understand that the largest healthcare issue today is the challenge of increasing capacity without increasing providers. That`s why we`ve developed innovative solutions that utilize technology to streamline the treatment process and optimize resource allocation. By harnessing the power of asynchronous medicine and AI, we are able to provide patients with fast and efficient access to care, while also freeing up physician time to focus on more complex and critical cases. At HelixVM, we believe that by empowering patients and providers with the tools they need to deliver and receive high-quality care, we can help to transform the healthcare industry. Whether you`re a physician looking for a more efficient and rewarding way to practice medicine, or a patient seeking convenient and accessible care, we are here to help. Join us on our mission to revolutionize healthcare delivery and improve patient outcomes.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."